首站-论文投稿智能助手
典型文献
Development and evaluation of the screening performance of a low-cost high-risk screening strategy for breast cancer
文献摘要:
Objective: To develop and evaluate the screening performance of a low-cost high-risk screening strategy for breast cancer in low resource areas. Methods: Based on the Multi-modality Independent Screening Trial, 6 questionnaire-based risk factors of breast cancer (age at menarche, age at menopause, age at first live birth, oral contraceptive, obesity, family history of breast cancer) were used to determine the women with high risk of breast cancer. The screening performance of clinical breast examination (CBE), breast ultrasonography (BUS), and mammography (MAM) were calculated and compared to determine the optimal screening method for these high risk women. Results: A total of 94 breast cancers were detected among 31,720 asymptomatic Chinese women aged 45–65 years. Due to significantly higher detection rates (DRs) and suitable coverage of the population, high risk women were defined as those with any of 6 risk factors. Among high risk women, the DR for BUS [3.09/1,000 (33/10,694)] was similar to that for MAM [3.18/1,000 (34/10,696)], while it was significantly higher than that for the CBE [1.73/1,000 (19/10,959), P = 0.002]. Compared with MAM, BUS showed significantly higher specificity [98.64% (10,501/10,646) vs. 98.06% (10,443/10,650), P = 0.001], but no significant differences in sensitivity [68.75% (33/48) vs. 73.91% (34/46)], positive prediction values [18.54% (33/178) vs. 14.11% (34/241)], and negative prediction values [99.86% (10,501/10,516) vs. 99.89% (10,443/10,455)]. Further analyses showed no significant difference in the percentages of early stage breast cancer [53.57% (15/28) vs. 50.00% (15/30)], lymph node involvement [22.73% (5/22) vs. 28.00% (7/25)], and tumor size ≥ 2 cm [37.04% (10/27) vs. 29.03% (9/31)] between BUS and MAM. Subgroup analyses stratified by breast densities or age at enrollment showed similar results. Conclusions: The low-cost high-risk screening strategy based on 6 questionnaire-based risk factors was an easy-to-use method to identify women with high risk of breast cancer. Moreover, BUS and MAM had comparable screening performances among high risk women.
文献关键词:
作者姓名:
Yubei Huang;Huan Wang;Zhangyan Lyu;Hongji Dai;Peifang Liu;Ying Zhu;Fengju Song;Kexin Chen
作者机构:
Department of Cancer Epidemiology and Biostatistics,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy of Tianjin,Tianjin's Clinical Research Center for Cancer,Key Laboratory of Cancer Molecular Epidemiology of Tianjin,Key Laboratory of Breast Cancer Prevention and Therapy,Ministry of Education,Tianjin 300060,China;Department of Breast Imaging,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy of Tianjin,Tianjin's Clinical Research Center for Cancer,Key Laboratory of Cancer Molecular Epidemiology of Tianjin,Key Laboratory of Breast Cancer Prevention and Therapy,Ministry of Education,Tianjin 300060,China
引用格式:
[1]Yubei Huang;Huan Wang;Zhangyan Lyu;Hongji Dai;Peifang Liu;Ying Zhu;Fengju Song;Kexin Chen-.Development and evaluation of the screening performance of a low-cost high-risk screening strategy for breast cancer)[J].癌症生物学与医学(英文版),2022(09):1375-1384
A类:
menarche
B类:
Development,evaluation,screening,low,cost,risk,strategy,breast,Objective,To,develop,evaluate,resource,areas,Methods,Based,Multi,modality,Independent,Screening,Trial,questionnaire,factors,menopause,first,live,birth,oral,contraceptive,obesity,family,history,were,used,determine,women,clinical,examination,CBE,ultrasonography,BUS,mammography,MAM,calculated,compared,optimal,method,these,Results,total,cancers,detected,among,asymptomatic,Chinese,aged,years,Due,significantly,higher,detection,rates,DRs,suitable,coverage,population,defined,those,any,Among,was,similar,that,while,than,Compared,showed,specificity,but,differences,sensitivity,positive,prediction,values,negative,Further,analyses,percentages,early,stage,lymph,node,involvement,tumor,size,between,Subgroup,stratified,by,densities,enrollment,results,Conclusions,easy,identify,Moreover,had,comparable,performances
AB值:
0.455991
相似文献
Can acupuncture enhance therapeutic effectiveness of antidepressants and reduce adverse drug reactions in patients with depression?A systematic review and meta-analysis
Ming-min Xu;Pei Guo;Qing-yu Ma;Xuan Zhou;Yu-long Wei;Lu Wang;Yue Chen;Yu Guo-School of Traditional Chinese Medicine,Jinan University,Guangzhou 510632,Guangdong Province,China;Acupuncture and Tuina School/Third Teaching Hospital,Chengdu University of Traditional Chinese Medicine,Chengdu 610075,Sichuan Province,China;School of Medicine,Chengdu University of Traditional Chinese Medicine,Chengdu 610075,Sichuan Province,China;Guangzhou Key Laboratory of Formula-Pattern of Traditional Chinese Medicine,Formula-Pattern Research Center,Jinan University,Guangzhou 510632,Guangdong Province,China;School of Acupuncture-Moxibustion and Tuina,Beijing University of Chinese Medicine,Beijing 100029,China
Risk of gestational diabetes recurrence and the development of type 2 diabetes among women with a history of gestational diabetes and risk factors: a study among 18 clinical centers in China
Wei Yumei;Juan Juan;Su Rina;Song Geng;Chen Xu;Shan Ruiqin;Li Ying;Cui Shihong;Fan Shangrong;Feng Ling;You Zishan;Meng Haixia;Cai Yan;Zhang Cuilin;Yang Huixia-Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing 100034, China;Department of Obstetrics, Tianjin Central Obstetrics and Gynecology Hospital, Tianjin 300199, China;Department of Obstetrics, Jinan Maternal and Child Health Hospital, Jinan, Shandong 250000, China;Department of Obstetrics, Dalian Maternity Hospital, Dalian, Liaoning 116033, China;Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China;Department of Obstetrics, Shenzhen Peking University Hospital, Shenzhen, Guangdong 518036, China;Department of Obstetrics and Gynecology, Tongji Hospital Affiliated to Huazhong University of Science and Technology, Wuhan, Hubei 430030, China;Department of Obstetrics and Gynecology, Suzhou Jiulong Hospital Affiliated to Shanghai Jiaotong University, Suzhou, Jiangsu 320571, China;Department of Obstetrics, Affiliated Hospital of Inner Mongolia Medical University, Huhhot, Inner Mongolia 010050, China;Department of Obstetrics and Gynecology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, China;Epidemiology Branch, Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20817, USA
Sex disparity of lung cancer risk in non-smokers: a multicenter population-based prospective study based on China National Lung Cancer Screening Program
Wu Zheng;Tan Fengwei;Yang Zhuoyu;Wang Fei;Cao Wei;Qin Chao;Dong Xuesi;Zheng Yadi;Luo Zilin;Zhao Liang;Yu Yiwen;Xu Yongjie;Ren Jiansong;Shi Jufang;Chen Hongda;Li Jiang;Tang Wei;Shen Sipeng;Wu Ning;Chen Wanqing;Li Ni;He Jie-Office of Cancer Screening, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;Key Laboratory of Cancer Data Science, Chinese Academy of Medical Sciences, Beijing 100021, China;Department of Thoracic Surgery, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;PET-CT Center, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, China;Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, Jiangsu 211166, China;Department of Diagnostic Radiology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Evaluation of triage strategies for high-risk human papillomavirus-positive women in cervical cancer screening:A multicenter randomized controlled trial in different resource settings in China
Le Dang;Linghua Kong;Yuqian Zhao;Yi Dai;Li Ma;Lihui Wei;Shulan Zhang;Jihong Liu;Mingrong Xi;Long Chen;Xianzhi Duan;Qing Xiao;Guzhalinuer Abulizi;Guonan Zhang;Ying Hong;Qi Zhou;Xing Xie;Li Li;Mayinuer Niyazi;Zhifen Zhang;Jiyu Tuo;Yiling Ding;Youlin Qiao;Jinghe Lang-Department of Gynecology and Obstetrics,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences/Peking Union Medical College,Beijing 100730,China;National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Center for Cancer Prevention Research,Sichuan Cancer Hospital and Institute,Sichuan Cancer Center,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610041,China;Department of Epidemiology,Dalian Medical University,Dalian 116044,China;Department Obstetrics and Gynecology,Peking University People's Hospital,Beijing 100044,China;Department of Obstetrics and Gynecology,Shengjing Hospital Affiliated to China Medical University,Shenyang 110004,China;Department of Gynecology and Obstetrics,Sun Yat-sen University Cancer Center,Guangzhou 510060,China;Department of Gynecology and Obstetrics,West China Second University Hospital,Sichuan University,Chengdu 610041,China;Department of Gynecology and Obstetrics,Zhejiang Xiaoshan Hospital Affiliated to Hangzhou Normal University,Chinese Academy of Medical Sciences/Zhejiang Xiaoshan Hospital Affiliated to Hangzhou Normal University,Hangzhou 310000,China;Department of Obstetrics and Gynecology,Beijing Tongren Hospital,Capital Medical University,Beijing 100730,China;Department of Gynecology and Obstetrics,the Eight Affiliated Hospital Sun Yat-sen University,Shenzhen 518000,China;125th Department of Gynecology,the Affiliated Cancer Hospital of Xinjiang Medical University,Urumqi 830011,China;Department of Gynecologic Oncology,Sichuan Cancer Hospital&Institute,Sichuan Cancer Center,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610041,China;Department of Gynecology and Obstetrics,Nanjing Drum Tower Hospital,Affiliated Hospital of Nanjing University Medical School,Nanjing 210008,China;Department of Gynecological Oncology,Chongqing University Cancer Hospital/Chongqing Cancer Hospital,Chongqing 400030,China;Department of Gynecologic Oncology,Women's Hospital,School of Medicine Zhejiang University,Hangzhou 310006,China;Department of Gynecology and Obstetrics,Tumor Hospital of Guangxi Zhuang Autonomous Region,Nanning 530021,China;Department of Gynecology,People's Hospital of Xinjiang Uygur Autonomous Region,Urumqi 830000,China;Department of Gynecology,Hangzhou Women's Hospital,Hangzhou 310016,China;Department of Gynecology and Obstetrics,Hubei Cancer Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430079,China;Department of Gynecology and Obstetrics,the Second Xiangya Hospital of Central South University,Changsha 410011,China;School of Population Medicine and Public Health,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100005,China
Adjuvant tamoxifen switched to exemestane treatment in postmenopausal women with estrogen receptor-positive early breast cancer: A pragmatic, multicenter, and prospective clinical trial in China
Binghe Xu;Huiping Li;Zefei Jiang;Lin Gu;Jinhai Tang;Hui Xie;Yueyin Pan;Yunjiang Liu;Shude Cui;Xiaojia Wang;Li Cai;Yiqiong Zhang;Huadong Zhao;Zhimin Shao-Department of Medical Oncology,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Breast Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Department of Breast Cancer,the Fifth Medical Center of Chinese PLA General Hospital,Beijing 100071,China;Department of Breast Cancer,Tianjin Cancer Institute and Hospital,Tianjin 300060,China;Department of Breast Cancer,Jiangsu Provincial Hospital,Nanjing 210029,China;Department of Breast Cancer,the First Affiliated Hospital of China University of Science and Technology,Hefei 230001,China;Department of Breast Cancer,the Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China;Department of Breast Cancer,Henan Cancer Hospital,Zhengzhou 450008,China;Department of Breast Cancer,Zhejiang Cancer Hospital,Hangzhou 310012,China;Department of Breast Cancer,Harbin Medical University Cancer Hospital,Harbin 150081,China;Department of Clinical Development,Pfizer(China)R&D Co.Ltd,Shanghai 201203,China;Department of Statistics,Pfizer(China)R&D Co.Ltd,Shanghai 201203,China;Department of Breast Surgery,Shanghai Cancer Center/Cancer Institute,Shanghai Medical College,Fudan University,Shanghai 200032,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。